12/7/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Cortimyk

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
1 1
1 1

Hydrokortison – lokalt

Hydrokortison – lokalt

Klass : 1

Visa all info

Skriv ut

Kontakta oss

  1. Tromm A, Möllmann H, Barth J, Hochhaus G, Krieg M, Bigalke C et al. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol. 2001;41(5):536-41.

  2. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.

  3. Wester RC, Maibach HI. Percutaneous absorption of topical corticosteroids. Curr Probl Dermatol. 1993;21:45-60.

  4. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.

  5. Jimenez-Solem E, Petersen KM, Poulsen HE, Petersen M, Jensen TB, Christensen M, Andersen JT. Topical pharmacological treatment of hemorrhoids during pregnancy and congenital malformations - a nation-wide cohort study. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2018;WCP2018:PO3-5–16.

  1. Tromm A, Möllmann H, Barth J, Hochhaus G, Krieg M, Bigalke C et al. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol. 2001;41(5):536-41.
  2. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.
  3. Wester RC, Maibach HI. Percutaneous absorption of topical corticosteroids. Curr Probl Dermatol. 1993;21:45-60.
  4. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.
  5. Jimenez-Solem E, Petersen KM, Poulsen HE, Petersen M, Jensen TB, Christensen M, Andersen JT. Topical pharmacological treatment of hemorrhoids during pregnancy and congenital malformations - a nation-wide cohort study. Proceedings for Annual Meeting of The Japanese Pharmacological Society. 2018;WCP2018:PO3-5–16.
2 2
2 2

Mikonazol

Mikonazol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Läkemedelsverket. Daktacort Produktresumé. Läkemedelsverket [www]. [updated 2020-06-01, cited 2024-10-25].

  2. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs. 1980;19(1):7-30.

  3. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

  4. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.

  5. Czeizel AE, Kazy Z, Puhó E. Population-based case-control teratologic study of topical miconazole. Congenit Anom (Kyoto). 2004;44(1):41-5.

  6. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA. 1981;246:343-6.

  7. Rotem R, Fishman B, Daniel S, Koren G, Lunenfeld E, Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018;125(12):1550-1556.

  8. Daniel S, Rotem R, Koren G, Lunenfeld E, Levy A. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol. 2018;218(6):601e1-601e7.

  1. Läkemedelsverket. Daktacort Produktresumé. Läkemedelsverket [www]. [updated 2020-06-01, cited 2024-10-25].
  2. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs. 1980;19(1):7-30.
  3. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.
  4. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.
  5. Czeizel AE, Kazy Z, Puhó E. Population-based case-control teratologic study of topical miconazole. Congenit Anom (Kyoto). 2004;44(1):41-5.
  6. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA. 1981;246:343-6.
  7. Rotem R, Fishman B, Daniel S, Koren G, Lunenfeld E, Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018;125(12):1550-1556.
  8. Daniel S, Rotem R, Koren G, Lunenfeld E, Levy A. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol. 2018;218(6):601e1-601e7.